CMPS

#2337
COMPASS Pathways Plc American Depository Shares
6.9000
-3.77%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
6.9000
6.9000
Intervallo Annuale
4.9000
8.9000
Variazione giornaliera
-3.77%
Variazione Mensile
-1.85%
Variazione di 6 mesi
+8.32%
Variazione Annuale
+8.32%
Chiusura Precedente
7.1700
Open
6.9000
Bid
Ask
Low
6.9000
High
6.9000
Volume
62
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
  • Market Capitalization 657.8322 M
  • Employee 166
  • Founded 2016
  • CEO N/A
  • Website compasspathways.com
  • Headquarter United Kingdom
  • FIGI BBG00X0VY2N1
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.64
Price to sales ratio
247.18
Dividends per share
—
Dividend yield %
—

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Notizie